Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06296706 | A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | PHASE3 | RECRUITING | 630 | — | — | Feb 27, 2024 | Jun 1, 2027 | Nov 14, 2024 | 1 | China |
Overall survival (OS)
| Arm | Type | Description |
|---|---|---|
| Docetaxel for Injection (Albumin-bound) | EXPERIMENTAL | Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks. |
| Taxotere (Docetaxel) | ACTIVE_COMPARATOR | Taxotere will be administrated by intravenous infusion once every 3 weeks. |
| Name | Type | Description |
|---|---|---|
| Docetaxel for injection (Albumin-bound) | DRUG | Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks |
| Taxotere (docetaxel) | DRUG | Taxotere, by intravenous infusion, every 3 weeks. |
Inclusion Criteria: * 1\. Age: 18-75 years (inclusive) (Whichever is on the day of signing the informed consent form). * 2\. Gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction confirmed by histology or cytology. * 3\. Locally advanced or metastatic gastric adenocarcinoma or adeno...